Companies
Pfizer
Targeted therapies — Off-target mitigation.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $62.6 billion for full-year 2025 | annualreview.pfizer.com |
| Capacity | 1 million kilograms of active pharmaceutical ingredients and 10 million kilograms of intermediates every year (Kalamazoo site) | pfizercentreone.com |
| Production site | Pearl River, NY and North Creek, WA (dedicated ADC manufacturing) | pfizercentreone.com |
| Production site | 13 manufacturing and distribution facilities in the United States | annualreview.pfizer.com |
| Certification | cGMP-compliant ADC manufacturing sites | pfizercentreone.com |
| Regulatory approval | FDA, EMA, PMDA, Health Canada, MHRA, Swissmedic, HAS, ANVISA, NMPA, TGA, Korean FDA, GCC/GCC-DR, AIFA, COFEPRIS, Turkish MoH, Taiwanese MoH, EAEU, MOITRF, Kazakhstan, and Belarus | pfizercentreone.com |
| Headcount | nearly 40% of Pfizer colleagues work in the global network (as of 2025) | annualreview.pfizer.com |
| Funding | $8.8 billion in business development transactions (2025) | syneticx.com |
Independent sources: syneticx.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| In-vivo gene therapy: AAV and lentiviral vectors | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.